Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 172,300 shares, a drop of 36.2% from the February 13th total of 270,200 shares. Based on an average daily trading volume, of 570,800 shares, the short-interest ratio is currently 0.3 days. Currently, 6.5% of the shares of the company are short sold.
Hedge Funds Weigh In On Traws Pharma
A number of institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $89,000. Renaissance Technologies LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $89,000. Geode Capital Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $185,000. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth $252,000. Finally, Vestal Point Capital LP purchased a new position in shares of Traws Pharma in the 4th quarter worth $666,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.
Traws Pharma Trading Down 0.7 %
TRAW stock opened at $2.74 on Friday. The stock has a market cap of $10.00 million, a P/E ratio of -0.02 and a beta of 1.42. Traws Pharma has a 1 year low of $2.02 and a 1 year high of $24.75. The business has a fifty day moving average price of $5.72.
Traws Pharma Company Profile
Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
Further Reading
- Five stocks we like better than Traws Pharma
- What is a Special Dividend?
- How to Build the Ultimate Everything ETF Portfolio
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Use Stock Screeners to Find Stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.